推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear (Warmed)
储存温度
-10 to -25°C
SMILES字符串
[Mg+2].S(C)c4ccc(cc4)c5[n](c(cc5)C)CCOc6ccc(cc6)C[C@H](OCC)C(=O)[O-].S(C)c1ccc(cc1)c2[n](c(cc2)C)CCOc3ccc(cc3)C[C@H](OCC)C(=O)[O-]
InChI
1S/2C25H29NO4S.Mg/c2*1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20;/h2*5-14,24H,4,15-17H2,1-3H3,(H,27,28);/q;;+2/p-2/t2*24-;/m00./s1
InChI key
UJYFZCVPOSZDMK-YPPDDXJESA-L
生化/生理作用
Potent and selective PPARα/γ agonist.
Saroglitazar is a potent and selective PPARα/γ (peroxisome proliferator-activated receptor) agonist that exhibits lipid-lowering and insulin-sensitizing effects. Saroglitazar is approved in India for the treatment of diabetes type 2 and dyslipidemia.
Saroglitazar is a potent and selective PPARα/γ (peroxisome proliferator-activated receptor) agonist that exhibits lipid-lowering and insulin-sensitizing effects. Saroglitazar is approved in India for the treatment of diabetes type 2 and dyslipidemia.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
从最新的版本中选择一种：
分析证书(COA)
Lot/Batch Number
Saroglitazar, a novel dual PPAR-?/? agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice
Life Sciences, 271, 119191-119191 (2021)
Saroglitazar, a novel PPAR?/? agonist with predominant PPAR? activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
Pharmacology Research & Perspectives, 3(3) (2015)
Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue
European Journal of Pharmacology, 822, 32-42 (2018)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门